Scottish scientists have helped discover a way to stop active cancer cells in their tracks – allowing them to then be eliminated by new drug treatments.

A research project between the University of Dundee’s Drug Discovery Unit (DDU) and Queen Mary University of London has identified chemical compounds, called tool molecules, that can halt active cancer cells.

Using these tool molecules forces tumour cells from a specific type of breast cancer into a pro-senescence state – similar to a sleep-like state, where they can no longer divide or cause tumour growth.

Read more: Cancer study reveals lower Scotland treatment levels

This condition makes the cancer cells sensitive to a second group of tool molecules, called senolytic drugs, which can eliminate them. It may also ‘uncloak’ the cancer cells, making them visible to the body’s immune system, offering further therapeutic opportunities.

Researchers developed this ‘two-punch’ method while looking at basal-like breast cancer (BLBC). 
A team funded by Barts Charity, and led by Cleo Bishop, professor of senescence at Queen Mary University of London, uncovered a pathway to force BLBC cells into pro-senescence.

The Herald: The Queen Mary University of London research teamThe Queen Mary University of London research team (Image: Contributed)

They then collaborated with the team based at the University of Dundee’s DDU to develop tool molecules to promote senescence within the cells.

Drug treatments to deliver the ‘second punch’ of cell elimination are currently being developed elsewhere.

Professor Bishop said: “At present, the most common treatments for BLBC are surgery and unsophisticated chemotherapy regimens. 

“Consequently, the lack of possible targets for tailored therapies and the aggressive clinical course means that women with BLBC have a particularly poor prognosis. 

“Pro-senescence therapies activate a stable cell cycle arrest halting tumour growth, trigger anti-tumour immune responses and expose cancers to novel treatment regimes called senolyitcs.” 

Read more: Cancer causing chemical used 200 times by fish farming industry

This research utilised high-content imaging to identify the tool molecules from DDU’s diversity libraries, which have now been selected by pharmaceutical company ValiRx for further evaluation.

The University of Dundee has this month signed a five-year agreement with the company, which focuses on early-stage cancer therapeutics and women’s health.

Charlotte Green, head of business development at the University of Dundee’s DDU, said: “The one-two punch approach has gained lots of interest in recent years but currently there is no clinical precedent, by moving the project forward with ValiRx we are leading the way in translating the research to the clinic.”

The pro-senescent ‘first punch’ tool molecules are the first to enter into a 12 month evaluation phase under this agreement and if successful, could result in a new company being established as a joint venture with all three parties.

ValiRx CEO Dr Suzy Dilly said: “The strength of the DDU and research facilities at Dundee are very impressive, and having reviewed multiple projects from teams there over the past year, we believe that this evaluation agreement will be the first of a series of new projects that can be brought into our pipeline.”